Sort   by:  
 Page size 
UnknownCSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.
Not available
S-EPMC10499811 | biostudies-literature
UnknownDrug delivery strategies to cross the blood-brain barrier in Alzheimer's disease: a comprehensive review on three promising strategies.
Not available
S-EPMC12321624 | biostudies-literature
UnknownAmyloid-β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old.
Not available
S-EPMC7886045 | biostudies-literature
UnknownOutcomes of clinical utility in amyloid-PET studies: state of art and future perspectives.
Not available
S-EPMC8175294 | biostudies-literature
UnknownPLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment.
Not available
S-EPMC7244617 | biostudies-literature
UnknownGenome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.
Not available
S-EPMC5414086 | biostudies-literature
UnknownThe Meta VCI Map consortium for meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping: Design and multicenter pilot study.
Not available
S-EPMC6465616 | biostudies-literature
UnknownSUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.
Not available
S-EPMC4240204 | biostudies-literature
UnknownA nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.
Not available
S-EPMC6660501 | biostudies-literature
UnknownAssociation of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.
Not available
S-EPMC5786156 | biostudies-literature
Sort   by:  
 Page size